Investor's Business Daily on MSN
Why top 2% Palvella Therapeutics, up 33%, just blew past its 50-day line
Biotech stock Palvella Therapeutics surged Tuesday on positive test results for its experimental skin disease treatment.
The field of cellular neuroscience continues to reveal the intricate regulation of neural and glial cell function by water and ion channels, transporters, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results